Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
On August 9, 2023, the U.S. Food and Drug Administration (FDA) approved pralsetinib (trade name: Gavreto, developed by Genentech) for regular use in adult patients with metastatic ···【more】
Article source：Captain MedicineRelease date：2026-01-15Recommended：22
Pralsetinib is indicated for the treatment of patients with metastatic (spread) non-small cell lung cancer (NSCLC) whose tumors harbor a RET fusion-positive gene.Latest Price of Pr···【more】
Article source：Captain MedicineRelease date：2026-01-15Recommended：28
Pralsetinib is indicated for the treatment of patients with advanced or metastatic (spread) medullary thyroid carcinoma (MTC) whose tumors harbor abnormal RET genes (RET-mutant typ···【more】
Article source：Captain MedicineRelease date：2026-01-15Recommended：29
As a novel AKT inhibitor, the drug interactions of capivasertib represent a critical aspect that must be prioritized in clinical practice.Which Drugs Interact with Capivasertib?Con···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：31
Although capivasertib offers a new treatment option for specific cancers, its efficacy and safety are highly susceptible to the impact of concomitant medications, making it crucial···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：30
Do not take other medications unless you have discussed them with your doctor. This includes prescription or over-the-counter (OTC) medicines, as well as herbal remedies or vitamin···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：35
This medicine may affect your blood glucose levels. If you experience increased thirst or frequent urination, consult your doctor immediately. If you notice any changes in your uri···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：33
Capivasertib (trade name: Truqap) is an oral pan-AKT inhibitor. In combination with fulvestrant, it is indicated for the treatment of locally advanced or metastatic hormone recepto···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：30
Capivasertib (trade name: Truqap) is the world’s first approved AKT inhibitor targeted drug, currently indicated primarily for combination therapy with fulvestrant in the treatment···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：29
Capivasertib is an investigational serine/threonine kinase (AKT) inhibitor.Is Capivasertib Effective in Treatment?The CAPItello-291 study is a phase III, double-blind, randomized c···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：33
Capivasertib is an oral kinase inhibitor that targets all three isoforms of the AKT enzyme (AKT1, AKT2, and AKT3).How Effective is Capivasertib?The CAPItello-291 study is a phase Ⅲ···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：29
Drugs used to treat cancer are usually highly potent and may cause numerous side effects. Before using this medication, ensure that you understand all its risks and benefits. It is···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：35
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3672024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：792025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：932025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
